Comparison of the effect of Laos version of Enasidenib with the original research

Enasidenib , as a targeted drug targeting IDH2 mutations, has been on the market overseas for many years and has accumulated certain application experience in the treatment of acute myeloid leukemia (AML). Due to the high price of original drugs, some countries and regions have begun to produce generic versions to reduce the economic burden of medication on patients. As one of the countries with the rapid development of the pharmaceutical industry in Southeast Asia, Laos has many pharmaceutical manufacturers launching generic ensidipine drugs. The more common manufacturers include Lucius Pharmaceuticals, Daxiong Pharmaceuticals, United Pharmaceuticals and ASEAN Pharmaceuticals. Common specifications include 50 mg 30 tablets and 100 mg 30 tablets. Each box may be sold for more than 1,000 yuan, which has obvious price advantages compared with overseas original drugs.

In terms of drug ingredients, the Laos version of ensidipine is consistent with the original drug in terms of main active ingredients, that is, both areIDH2 inhibitors. According to international generic drug standards, generic drugs need to pass bioequivalence verification to ensure that their absorption, distribution and metabolism in the body are close to those of the original drugs, thereby ensuring similar efficacy. Therefore, theoretically speaking, the Laos version is not fundamentally different from the original drug in terms of mechanism and effect. Some patients also believe that it has a certain effect in improving their condition in clinical use feedback.

However, original drugs usually undergo large-scale clinical trials to confirm their efficacy and safety, and have stricter regulatory standards in terms of production processes, impurity control and stability. Although generic drugs in Laos generally follow international standards, they are limited by regional differences and their quality control system and long-term follow-up data may not be as complete as those in the European and American markets, which makes some doctors more cautious when recommending their use. For patients, the biggest driver of choosing generic drugs is often affordability, and if family conditions are limited, the Lao version provides more treatment opportunities. If conditions permit, original drugs are still a safer choice.

Reference materials:https://www.idhifa.com/